C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
Current SymbolNYSE:BCR
Previous Symbol
CUSIP06738310
Phone+1-908-2778000
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees16,300
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
C R Bard (NYSE:BCR) Frequently Asked Questions
What is C R Bard's stock symbol?
C R Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR."
How were C R Bard's earnings last quarter?
C R Bard Inc (NYSE:BCR) issued its quarterly earnings data on Wednesday, October, 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $2.96 by $0.06. The medical instruments supplier had revenue of $989.80 million for the quarter, compared to analyst estimates of $990.64 million. The company's revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.64 earnings per share. View C R Bard's Earnings History.
Has C R Bard been receiving favorable news coverage?
Media stories about BCR stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. C R Bard earned a news sentiment score of 0.6 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the near term.
Who are C R Bard's key executives?
C R Bard's management team includes the folowing people:
- Timothy M. Ring, Chairman of the Board, Chief Executive Officer (Age 59)
- John H. Weiland, President, Vice Chairman of the Board, Chief Operating Officer (Age 61)
- James C. Beasley, Group President (Age 53)
- Timothy P. Collins, Group President (Age 56)
- John P. Groetelaars, Group President (Age 50)
- Christopher S. Holland, Chief Financial Officer, Senior Vice President (Age 50)
- Samrat S. Khichi, Senior Vice President, General Counsel, Secretary (Age 49)
- John A. DeFord Ph.D., Senior Vice President - Science, Technology and Clinical Affairs (Age 55)
- Frank Lupisella Jr., Vice President, Controller (Age 56)
- Betty D. Larson, Vice President - Human Resources (Age 41)
Who are C R Bard's major shareholders?
C R Bard's stock is owned by a number of of institutional and retail investors. Top institutional investors include Kentucky Retirement Systems (0.00%). Company insiders that own C R Bard stock include Betty D Larson, Christopher S Holland, David M Barrett, Frank Lupisella Jr, Frank Lupisella, Jr, Gail K Naughton, Jim C Beasley, John A Deford, John H Weiland, John P Groetelaars, Sharon M Luboff, Timothy M Ring and Timothy P Collins. View Institutional Ownership Trends for C R Bard.
Which institutional investors are buying C R Bard stock?
How do I buy shares of C R Bard?
Shares of BCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is C R Bard's official website?
How can I contact C R Bard?
C R Bard's mailing address is 730 Central Ave, NEW PROVIDENCE, NJ 07974-1139, United States. The medical instruments supplier can be reached via phone at +1-908-2778000.
MarketBeat Community Rating for C R Bard (NYSE BCR)
MarketBeat's community ratings are surveys of what our community members think about C R Bard and other stocks. Vote "Outperform" if you believe BCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
